We have previously reported that HL patients with many mast cells in their tumour tissue have a worse prognosis. 2 Mast cells produce functionally active CD30 ligand (CD30L) and the poorer prognosis has been proposed to be caused by a stimulation of HRS by CD30L. 3 Furthermore, we have shown that mast cells, upon stimulation with CD30, release cytokines and chemokines, among which interleukin-8 (IL-8) is known to have angiogenic properties (manuscript in preparation). In other lymphomas, mast cells are proposed to contribute to angiogenesis. 4 In order to increase our understanding of inflammatory cells, their importance in tumour progression and especially angiogenesis in HL, we investigated the possible relation between the number of mast cells and the microvessel count in primary diagnostic HL tissue. We also wanted to further elucidate the prognostic implication of microvessel count in HL.
Patient samples and clinical data were acquired from the database of the National Health Care Programme for HL in Sweden. A total of 120 patients treated with curative intention, according to the principles of the Health Care Programme 2 in the Uppsala/Ö rebro health care region between 1989 and 1994, were included. The paraffin-embedded tissue samples were from HL involved lymph nodes from the primary diagnosis. The clinical characteristics are presented in Table 1 . Progression free survival (PFS) and HL specific survival (HLS) were analysed. The mean follow-up of living patients was 11 years (range 6-15 years).
The estimation of the number of microvessels immunohistochemically stained for CD31 (Figure 1) , was done by one of the authors using the Chalkley technique. 5 Three to five fields with the highest concentration of vessels (a hot spot) were counted and an average of the highest three countings in every case was used. In all, 20 cases were recounted independently by another author and the counts correlated with an R-value of 0.75, (P ¼ 0.0002). All evaluations were done without knowledge of patient data. The counts varied from 1 to 12 vessels/hot spot. The median was 3 and the 75th percentile was 4.3 vessels/hot spot. Nonbulky disease correlated to high microvessel count (Table 1) and there was a lower proportion of patients with WBC415 in the upper quartile group (data not shown), but there were no other correlations to histology, laboratory parameters, stage, B-symptoms or sex.
In univariate analyses, HL patients with a high microvessel count, cutoff at the 75th percentile (n ¼ 33), have a worse PFS compared with those with a lower number of microvessels (Figure 2) . The 75th percentile resulted in the best separation in outcome compared to the 25th and 50th percentiles. The HLS was not significantly influenced by the number of vessels (P ¼ 0.17). When tested in a multivariate analysis against age and low s-albumin, the most powerful prognostic factors, the microvessel count was not statistically significantly related to PFS (P ¼ 0.10), probably due to the very strong influence of age on prognosis. The observed correlations between high number of microvessels and high age on the one hand (Table 1) and worse PFS, on the other hand ( Figure 2 ) are in line with the recent study by Korkolopoulou et al. 1 However, in that study a morphometric approach was used where they investigated different features of the microvessels. 1 It might be speculated that the higher number of microvessels in elderly patients points towards a biological difference between HL in younger and older patients.
Immunostaining and grouping according to the number of the tryptase positive mast cells ( Figure 3) were done in an earlier report on the same material and has thus been previously described. 2 Five additional cases were stained and counted. Mast cell data was missing for two patients because of lack of tumour material. Unexpectedly, a high microvessel count did not correlate to high number of mast cells (Spearman R ¼ 0.05, P ¼ 0.62). Neither were there any correlations between the cutoff level for vessels (4.3 vessels/hot spot) and the number of mast cells (Mann-Whitney U-test P ¼ 0.55), between the number of mast cells grouped into more or less than 10 and the absolute number of vessels (Mann-Whitney U-test P ¼ 1.00), or, as shown in Table 1 , between the groups of more or less than 10 mast cells, compared to the groups of few and many microvessels (w 2 test P ¼ 0.86). NS ¼ not significant.
Figure 2
Kaplan-Meier curve showing that patients (n ¼ 120) with high microvessel count, have a worse progression-free survival compared to patients with low microvessel count (P ¼ 0.03).
Figure 1
Hodgkin lymphoma tissue immunohistochemically stained with the monoclonal antiendothelial antibody, anti-CD31, at magnification Â 100; showing an area with many microvessels.
Correspondence
The poor prognosis, previously described by us, when many mast cells are found in the tumours 2 could thus not be explained by a higher microvessel count in the tumours. However, mast cells are the predominant CD30L expressing cells in HL 3 and CD30-CD30L activation is of importance for tumorgenesis in HL. 3 A plausible explanation for the poor prognosis in mast cell rich HL is therefore that the proliferation and activation of the tumour cells are enhanced by CD30L expressed by the mast cells. 3 The lack of correlation between high microvessel count and many mast cells in our study might indicate a different pathway for the proliferation of microvessels in HL compared to other lymphomas. 4 It is, however, still possible that mast cells contribute to microvessel stimulation, but this is not reflected in mast cell numbers. Mast cells express several factors that can affect angiogenesis both directly and indirectly, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, transforming growth factor-b, tumour necrosis factor-a, IL-8, histamine, tryptase, matrix metalloproteinase-9 and heparine. 6 Variations in the production and release of these factors by mast cells in HL, may be of greater relevance than the actual mast cell numbers. However, there are other possible pathways for vascularization in HL, for example, VEGF is produced by the HRS cells. 7 Eotaxin, expressed in HL, but not from the mast cells, 8 induces the formation of blood vessels. There are also other surrounding cells in the HL tumour tissue, which may influence vascularization, for example, macrophages. 6 Thus, several possible mechanisms for angiogenesis exist in HL and further elucidation is needed.
The best method to discriminate between blood and lymphatic vessels in lymph nodes is debated. Some authors claim that CD31 is the best discriminator whereas others favour CD34. 9, 10 In our study, the antiendothelial antibody CD31 was used to verify microvessels. In the study by Korkolopoulou et al 1 CD34 was used. With any of the methods so far used, it is, however, not possible to discriminate between newly formed and old microvessels.
In conclusion, this study adds further proof that high microvessel count is of importance for the prognosis in HL but there is no correlation to mast cell count. Instead, the correlation between mast cells and poor prognosis is probably due to, for example, CD30/CD30L interaction with the HRS cells.
Figure 3
Hodgkin lymphoma tissue immunohistochemically stained with the monoclonal antibody G3, recognising the mast cellspecific protein tryptase, at magnification Â 400; showing mast cells in brown. The arrow shows a Hodgkin cell.
